Laura Joszt

Cranbury, New Jersey

Vice President of Content at Pharmacy Times

Vice President of Content at American Journal of Managed Care

Vice President of Content at MJH Life Sciences

Vice President of Content at Chief Healthcare Executive

Editorial Director for @AJMC_Journal at @MJHLifeSciences

Featured in: Favicon

pharmacytimes.com Favicon

ajmc.com

mjhlifesciences.com Favicon

chiefhealthcareexecutive.com Favicon

hcplive.com Favicon

newsbreak.com Favicon

curetoday.com Favicon

medicaleconomics.com Favicon

dermatologytimes.com Favicon

managedhealthcareexecutive.com + 6 more

Articles

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

2 weeks ago | ajmc.com | Laura Joszt

Today, we are bringing you a conversation on the use of continuous glucose monitoring (CGM) technology and its transformative potential in diabetes care.
Dr Oz Confirmed by the Senate Along Party Lines to Lead CMS

3 weeks ago | ajmc.com | Laura Joszt

Author(s): Mehmet Oz, MD, confirmed as CMS head, with Senate vote reflecting party lines, 53-45. Oz, nominated by President Trump, will oversee Medicare and Medicaid, impacting millions. During his hearing, Oz focused on technology to streamline healthcare and improve efficiency. Emphasized nutrition and lifestyle's role in health, aligning with the MAHA movement led by HHS Secretary Robert F.
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC

1 month ago | ajmc.com | Laura Joszt

Despite receiving an initial complete response letter (CRL) on May 16, 2024,1 the resubmitted new drug application for rivoceranib (Elevar Therapeutics) plus camrelizumab (Antiengene Corporation) to treat unresectable hepatocellular carcinoma (HCC) received a second CRL, reported Korean news sources.2The initial CRL was due to deficiencies related to the inspection of the manufacturing site for camrelizumab, although there were no issues noted related to the manufacturing site for rivoceranib.
A Focus on MAHA, Lasting Changes to Health Care Programs for Trump’s Second Term

1 month ago | ajmc.com | Laura Joszt

The second Trump administration will be similar regarding health care to the first one, with very aggressive efforts to implement significant changes to most of the established health care programs in the country, according to Jim Parker, MBA, founder of JTP Advisors, a health care consulting firm.
Mortality Declines but Incidence Rates Up for Cirrhosis and Other Chronic Liver Diseases

1 month ago | ajmc.com | Laura Joszt

The global burden of cirrhosis and other chronic liver diseases remains high, and in the Americas, age-standardized deaths and disability-adjusted life-years (DALYs) related to metabolic dysfunction–associated steatohepatitis (MASH) have increased compared with other regions in the world.
Barriers That Prevent Access to Optimal Treatment in Primary Urethral Cancer

2 months ago | ajmc.com | Laura Joszt

Despite neoadjuvant chemotherapy followed by surgery providing a 7% increase in 5-year overall survival for patients with primary invasive urethral cancer, only 19% of patients actually receive this treatment.
Real-World Data Support First-Line Avelumab Plus Axitinib in Advanced RCC

2 months ago | ajmc.com | Laura Joszt |Courtney Flaherty |Axel S. Merseburger

A real-world analysis of avelumab and axitinib to treat advanced renal cell carcinoma supports the frontline use of the combination and confirmed the findings of JAVELIN Renal 101 (NCT02684006), said Axel Merseburger, MD, professor of urology and chairman of the Department of Urology, University Hospital Schleswig Holstein, Campus Lübeck, and director of the Urologic Oncology Program, Hannover Medical School in Germany.
The Evolving Annual Wellness Visit

2 months ago | ajmc.com | Laura Joszt |Christopher Wheelock

Today, we're diving deep into a crucial aspect of preventive healthcare: the annual wellness visit. Our guest is Christopher Wheelock, MD, a clinical transformation physician executive at Highmark Health, responsible for developing payer and provider collaborations to move toward value-based care. In the past, he was heavily involved with developing the workflow, patient scripting and templating for the annual wellness visit when CMS first established it in 2011 as part of the Affordable Care Act.
Top 5 Most-Read Obesity Articles in 2024

Dec 17, 2024 | businessandamerica.com | Laura Joszt

The conversation around obesity intensified in 2024 as the disease intersected with public health, health policy, and insurance coverage issues. Interest in glucagon-like peptide 1 (GLP-1) receptor agonists to treat obesity grew exponentially and demand far outpaced supply. Furthermore, research began to show the GLP-1s had a role in more than just weight loss. Here is the most-read obesity coverage of 2024, or you can read all of our coverage.
Access and Equity: Bispecifics for Multiple Myeloma in the Community Setting

Dec 11, 2024 | ajmc.com | Laura Joszt |Luke Halpern

Initial uptake of bispecific antibodies in the community setting has been strong, with good implications for increased access for patients with multiple myeloma (MM), but more data is needed on individual characteristics of patients receiving these therapies, such as social determinants of health and insurance type, explained Ira Zackon, MD, senior medical director, oncology research and insights, Ontada.